v3.22.2.2
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($)
Preferred Stock
Series Seed Preferred Stock
Preferred Stock
Series A preferred stock
Preferred Stock
Series A-2 preferred stock
Preferred Stock
Series A-3 preferred stock
Preferred Stock
Series CF preferred stock
Preferred Stock
Series B preferred stock
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Beginning balance (in shares) at Dec. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167      
Beginning balance at Dec. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 $ 27,481,995 $ (33,345,997) $ (5,857,645)
Stock-based compensation               36,976   36,976
Net loss                 (3,023,935) (3,023,935)
Ending balance at Mar. 31, 2021 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 27,518,971 (36,369,932) (8,844,604)
Ending balance (in shares) at Mar. 31, 2021 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167      
Beginning balance (in shares) at Dec. 31, 2020 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167      
Beginning balance at Dec. 31, 2020 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 27,481,995 (33,345,997) (5,857,645)
Conversion of preferred stock into common stock                   6,293
Conversion of notes and derivative liability into common stock                   2,680,289
Conversion of related party notes and payables into common stock                   257,515
Net loss                   (13,721,433)
Ending balance at Jun. 30, 2021             $ 1,104 51,939,819 (47,067,430) 4,873,493
Ending balance (in shares) at Jun. 30, 2021             11,044,594      
Beginning balance (in shares) at Mar. 31, 2021 20,714,518 5,654,072 5,932,742 9,032,330 836,331 20,754,717 664,167      
Beginning balance at Mar. 31, 2021 $ 2,071 $ 565 $ 593 $ 904 $ 83 $ 2,075 $ 66 27,518,971 (36,369,932) (8,844,604)
Conversion of preferred stock into common stock $ (2,071) $ (565) $ (593) $ (904) $ (83) $ (2,075) $ 403 5,888    
Conversion of preferred stock into common stock (shares) (20,714,518) (5,654,072) (5,932,742) (9,032,330) (836,331) (20,754,717) 4,027,181      
Issuance of common stock in public offering             $ 241 9,999,761   10,000,002
Issuance of common stock in public offering (in shares)             2,409,639      
Offering costs               (2,116,957)   (2,116,957)
Exercise of over-allotment option, net of offering costs             $ 36 1,364,961   1,364,997
Exercise of over-allotment option, net of offering costs (in shares)             361,445      
Conversion of notes and derivative liability into common stock             $ 114 2,680,175   2,680,289
Conversion of notes and derivative liability into common stock (In shares)             1,135,153      
Conversion of related party notes and payables into common stock             $ 15 257,500   257,515
Conversion of related party notes and payables into common stock (in shares)             152,357      
Common stock and warrants issued in connection with note             $ 2 73,956   73,958
Common stock and warrants issued in connection with note (in shares)             20,000      
Common stock issued in connection with business combination             $ 219 8,025,323   8,025,542
Common stock issued in connection with business combination (in shares)             2,192,771      
Exercise of warrants             $ 3 145,693   145,696
Exercise of warrants (in shares)             31,881      
Common stock issued pursuant to consulting agreement             $ 5 182,995   183,000
Common stock issued pursuant to consulting agreement (in shares)             50,000      
Stock-based compensation               3,801,553   3,801,553
Net loss                 (10,697,498) (10,697,498)
Ending balance at Jun. 30, 2021             $ 1,104 51,939,819 (47,067,430) 4,873,493
Ending balance (in shares) at Jun. 30, 2021             11,044,594      
Beginning balance (in shares) at Dec. 31, 2021             13,001,690      
Beginning balance at Dec. 31, 2021             $ 1,300 58,612,873 (65,703,954) (7,089,781)
Conversion of notes and derivative liability into common stock             $ 87 1,201,495   1,201,582
Conversion of notes and derivative liability into common stock (In shares)             873,901      
Stock-based compensation               139,093   139,093
Net loss                 (7,832,942) (7,832,942)
Ending balance at Mar. 31, 2022             $ 1,387 59,953,461 (73,536,896) (13,582,048)
Ending balance (in shares) at Mar. 31, 2022             13,875,591      
Beginning balance (in shares) at Dec. 31, 2021             13,001,690      
Beginning balance at Dec. 31, 2021             $ 1,300 58,612,873 (65,703,954) (7,089,781)
Conversion of notes and derivative liability into common stock                   1,802,372
Net loss                   (17,366,866)
Ending balance at Jun. 30, 2022             $ 5,287 68,185,315 (83,070,820) (14,880,218)
Ending balance (in shares) at Jun. 30, 2022             52,874,188      
Beginning balance (in shares) at Mar. 31, 2022             13,875,591      
Beginning balance at Mar. 31, 2022             $ 1,387 59,953,461 (73,536,896) (13,582,048)
Issuance of common stock in public offering             $ 3,739 9,343,711   9,347,450
Issuance of common stock in public offering (in shares)             37,389,800      
Offering costs               (1,930,486)   (1,930,486)
Conversion of notes and derivative liability into common stock             $ 161 600,629   600,790
Conversion of notes and derivative liability into common stock (In shares)             1,608,797      
Common stock and warrants issued in connection with note               98,241   98,241
Stock-based compensation               119,759   119,759
Net loss                 (9,533,924) (9,533,924)
Ending balance at Jun. 30, 2022             $ 5,287 $ 68,185,315 $ (83,070,820) $ (14,880,218)
Ending balance (in shares) at Jun. 30, 2022             52,874,188